<DOC>
	<DOCNO>NCT02372630</DOCNO>
	<brief_summary>This single center , prospective randomize double blind , parallel placebo control study evaluate oxidative stress inflammation treatment linagliptin 12 week . We also , test whether Linagliptin insulin sensitizer .</brief_summary>
	<brief_title>The Effect LINAGLIPTIN Inflammation , Oxidative Stress Insulin Resistance Obese Type 2 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Age 2080 year inclusive . Type 2 diabetes BMI ≥30 kg/m2 Subjects statin , ACE inhibitor , thiazolidenediones antioxidant allow long stable dos compound dosage change course study . HbA1c ≤ 8.0 % Use GLP1 agonists DPPIV therapy last 3 month . History Pancreatitis . Risk pancreatitis , i.e. , history gallstone , alcohol abuse , hypertriglyceridemia . Subjects take antiplatelet anticoagulant medication exclude fat biopsy portion study . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week Hepatic disease ( liver function test 3 time upper limit normal ) Renal impairment ( serum eGFR &lt; 30 ml/min ) Any lifethreatening , noncardiac disease Uncontrolled hypertension ( BP &gt; 160/100 mm Hg ) Congestive Heart Failure class III IV . Use investigational agent therapeutic regimen within 30 day study Participation concurrent clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>